Faster global financial news!
Roche
-
Hansoh Pharmaceutical inks up to $15B drug deal with Roche, China's innovative drug out-licensing hits $130B
Hong Kong-listed Hansoh Pharmaceutical Group announced a collaboration agreement with Swiss healthcare company F. Hoffmann-La Roche, potentially worth over $15 billion in development, regulatory appro
-
South Korean genomics company Macrogen adopts Roche's next-gen platform to speed up genome sequencing
South Korean genomics company Macrogen adopts Roche's next-gen platform to speed up genome sequencing
-
Roche-owned Chugai Pharma to boost in-house output with 50% capex increase
The Japanese drugmaker plans to invest around 100 billion yen ($635 million) annually in facilities and equipment by 2028, aiming to reduce outsourcing and cut costs.
-
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes
-
Hansoh Pharmaceutical inks up to $15B drug deal with Roche, China's innovative drug out-licensing hits $130B
Hong Kong-listed Hansoh Pharmaceutical Group announced a collaboration agreement with Swiss healthcare company F. Hoffmann-La Roche, potentially worth over $15 billion in development, regulatory appro
-
South Korean genomics company Macrogen adopts Roche's next-gen platform to speed up genome sequencing
South Korean genomics company Macrogen adopts Roche's next-gen platform to speed up genome sequencing
-
Roche-owned Chugai Pharma to boost in-house output with 50% capex increase
The Japanese drugmaker plans to invest around 100 billion yen ($635 million) annually in facilities and equipment by 2028, aiming to reduce outsourcing and cut costs.
-
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes
- No data
Roche
24H Trending
-
1
AI Tokens Explained: Definition, Key Projects, and Market Outlook for Artificial Intelligence Cryptocurrencies
-
2
What is NBM Coin (NFTBlackmarket)? Status and Trading Channels Analysis
-
3
Verizon Communications Inc. (VZ) Q3 Earnings Report Earnings Per Share (EPS): $1.31, market expectation $1.27 Revenue: $34.31 billion, market expectation $34.77 billion Reporting Period: FY2026 Q3 (ended September 30, 2026) Release Date: October 26, 2026
-
4
Brent crude prices fell below $110/barrel, down over 6% from Friday's high
-
5
Which Platforms Allow Bitcoin Purchases Now? A Guide to Choosing Bitcoin Trading Apps
-
6
Virtual Currency Exchange Review: Compliance and Risk Boundaries of Major Global Platforms
-
7
What is EURe? An Analysis of the Euro Stablecoin EURe's Features, Uses, and Trading Channels
-
8
Israel will hold general elections on Tuesday, with war, security, the economy, and coalition formation being the main issues
-
9
Will Cryptocurrencies Disappear? A Comprehensive Analysis of Their Survival Prospects and Challenges
-
10
Global Crypto Exchange Analysis: Largest Platforms and Best Application Choices
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
